Navigation Links
Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch
Date:9/26/2011

WATERTOWN, Mass., Sept. 26, 2011 /PRNewswire/ -- Enanta Pharmaceuticals, Inc. announced today that its lead development candidate from its NS5A hepatitis C virus (HCV) inhibitor program, EDP-239, has been recognized on Windhover's list of the "Top 10 Most Interesting Infectious Disease Projects to Watch." EDP-239 was chosen by independent experts at Windhover Information and Herndon Company.

NS5A, a clinically-validated target, is a non-structural viral protein that is essential to viral replication. Research efforts have shown that targeting NS5A gives rise to profound antiviral activity, and as a result, this protein has emerged as an important target for antiviral drug development. Enanta's NS5A program and intellectual property estate in the HCV field were derived from its internal drug discovery efforts.

"Enanta appreciates Windhover's recognition of our EDP-239 program for HCV, which showcases the strength of our internal drug discovery efforts aimed against important infectious disease targets," said Jay Luly, Ph.D, president and chief executive officer, Enanta Pharmaceuticals. "We are on-track to initiate a Phase 1 clinical trial for EDP-239 in the coming months, following preclinical studies that demonstrated picomolar potency against multiple genotypes of the virus, an excellent safety profile and a preclinical pharmacokinetic profile amenable to once-a-day dosing in humans."

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive infectious disease opportunities the industry has to offer," said David Cassak, Vice President, Content, Windhover Conferences, a division of Elsevier Business Intelligence.  "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma
'/>"/>

SOURCE Enanta Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
2. Modulation of inhibitory output is key function of antiobesity hormone
3. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
4. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
5. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
6. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
7. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
8. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
9. Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting
10. Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry
11. CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Rogne Bioscience, a privately-held biotechnology company based ... has acquired a licence to anti-inflammatory peptides from Isis ... anti-inflammatory activity of the peptides was discovered by Professor ... Sir William Dunn School of Pathology. ... million in seed financing, is developing a first-in-class, topical ...
(Date:7/31/2014)... CollabRx, Inc. (NASDAQ: CLRX), a leading ... oncology, today announced that it will hold an investor ... Company's financial results for the first quarter of fiscal ... in the current fiscal year. , The dial-in number ... 14, 2014, at 5 p.m. EDT (2 p.m. PDT) ...
(Date:7/31/2014)... San Diego, CA (PRWEB) July 31, 2014 ... company announced today the integration of Omicsoft’s Array Suite ... to both platforms will be able to send data ... The integration works with all versions of tranSMART including ... of the art statistics, visualization and storage for the ...
(Date:7/31/2014)... 31, 2014 SoundConnect , ... company, is proud to announce the addition of ... Adobe Connect’s elearning tools to quickly deploy and ... with training tools for desktop and mobile learning ... is the perfect online training solution, enabling organizations ...
Breaking Biology Technology:Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2
... 7, 2011 Cellectis (Alternext: ALCLS), the ... its nuclease production capacity has increased ten-fold ... of the nuclease manufacturing gives Cellectis bioresearch, ... of Cellectis, the potential to supply the ...
... , Inc. ( www.sermo.com ), the largest online physician ... of Sermo Sponsorship, a portfolio of offerings that provides ... to engage physicians and educate them on new products ... and mobile platforms, where physicians across 68 specialties discuss ...
... Sanford Rose Associates® - San Diego, focusing exclusively on assignments ... another successful placement. Mr. John Sperzel has been selected for ... a global provider of Point of Care testing systems and ... Directors. Mr. Sperzel is a dynamic business leader ...
Cached Biology Technology:Cellectis Announces a Ten-Fold Increase in Nuclease Production Capacity in 2011 2Sermo, Inc. Introduces New Sponsorship Product for Pharma, Biotech and Life Sciences 2Sermo, Inc. Introduces New Sponsorship Product for Pharma, Biotech and Life Sciences 3John Sperzel Appointed as Chief Executive Officer of ITC Nexus Dx 2
(Date:7/31/2014)... are the largest minority group in the United States, ... Latinos are obese and are 1.2 times as likely ... NYU College of Nursing student researcher Lauren Gerchow, BSN, ... that contribute to this problem by compiling a systematic ... in Latina women recently published in Nursing Research ...
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... team of scientists from Spain, France, and the ... that is the oldest definitive member of the ... amber. The discovery and description were made possible ... synchrotron imaging technique, which allows the detailed study ... new species is described in the journal ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... in spite of waves that sometimes pound the shore ... 600 miles per hour are more prone to snap ... the American Association for the Advancement of Science meeting in ... reported that the fibrous threads she calls "nature,s bungee cords" ...
... or impacted wisdom teeth? As we humans evolved ... brains and shorter jaws, bear big babies and live longer, ... becoming the world,s most successful primate, at nearly 7 billion ... help us better deal with issues from obesity to difficult ...
... the University of Huddersfield aims to ensure that the risk of ... lead plumbing is reduced even further in line with new ... The project is being conducted in collaboration with Yorkshire ... such as European nations and the USA, have similar issues with ...
Cached Biology News:Mussels cramped by environmental factors 2Mussels cramped by environmental factors 3Is there a Neanderthal in the house? 2Research with Yorkshire Water to reduce lead in water supplies 2
Applications: (+) Immunocytochemistry and immunohistochemistry...
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Non-Protein Peroxidase Stabilizer , 1 L...
... Lysate contains the cellular components necessary for ... elongation and termination factors) but has not ... is used primarily for the isolation of ... of endogenous globin mRNA. Untreated Lysate is ...
Biology Products: